The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
about
Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706Recent developments of protein kinase inhibitors as potential AD therapeuticsNicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal CompoundsDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTEffectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a reviewNicotinic ACh receptors in the hippocampal circuit; functional expression and role in synaptic plasticityMemantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's diseaseEvidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's diseaseAnimal models of intellectual disability: towards a translational approachTacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivoMolecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's diseaseWNT and beta-catenin signalling: diseases and therapiesTreatment guidelines for Alzheimer's disease: redefining perceptions in primary care.In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease.Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.Inhibition of acetylcholinesterase by two arylderivatives: 3a-Acetoxy-5H-pyrrolo (1,2-a) (3, 1)benzoxazin- 1,5-(3aH)-dione and cis-N-p-Acetoxy-phenylisomaleimide.Synthesis of New Functionalized Indoles Based on Ethyl Indol-2-carboxylate.NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.An Overview of the Protective Effects of Chitosan and Acetylated Chitosan Oligosaccharides against Neuronal Disorders.The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortexCalcium signaling and amyloid toxicity in Alzheimer disease.Age-related learning and memory deficits in rats: role of altered brain neurotransmitters, acetylcholinesterase activity and changes in antioxidant defense systemThe protective effect of fermented Curcuma longa L. on memory dysfunction in oxidative stress-induced C6 gliomal cells, proinflammatory-activated BV2 microglial cells, and scopolamine-induced amnesia model in mice.Intersection between metabolic dysfunction, high fat diet consumption, and brain aging.Neuroprotective properties of chitosan and its derivatives.Bioactive compounds from macroalgae in the new millennium: implications for neurodegenerative diseases.Magnetic resonance spectroscopy in vivo of neurochemicals in a transgenic model of Alzheimer's disease: a longitudinal study of metabolites, relaxation time, and behavioral analysis in TASTPM and wild-type mice.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Age-related memory impairments due to reduced blood glucose responses to epinephrine.Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.Translational Research on Nicotine Dependence.Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline.Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers.Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats.Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys.Alzheimer's disease and age-related memory decline (preclinical)Nicotinic versus muscarinic blockade alters verbal working memory-related brain activity in older women
P2860
Q21129335-17E7D538-E747-46AD-8CBE-BF2E27616C0EQ21129481-1B9E5237-734F-498E-8997-3B9C0B8D998EQ24532028-754B46E6-CCE9-4F18-9572-4C565856F2D6Q26749061-407AE5AD-79DE-49DD-8774-A0588CEEB71FQ26749755-1969F8AA-7AC4-4610-BF9A-2BFF7EBCDF9BQ26998916-7370F7ED-AB26-4654-A579-9C2DDB0A8BA9Q27005710-8F8C05F9-8FAD-4F5E-82D8-479CEB6CC417Q27025207-032ACC04-CF1A-446D-A183-62FC1EC21446Q28212725-FD8A622B-F548-4EBF-B57D-40F550398E4CQ28287100-550318FB-C2A6-41E3-B2CD-D5D505F4F45BQ28389500-89118B32-230C-4586-8C26-DCAF56EDA22EQ28481239-A2C9BB46-9517-4804-89D9-1F06AB37523DQ28542431-6F421CF5-C78D-456A-9751-F01363C18070Q29616159-F6ED81A2-B72D-4588-B487-E8B0FD5C9C46Q30443975-214818A6-1412-4600-BA9A-A844CAE2836EQ30495524-DB171A96-36EE-4438-A0F8-8C84E0D49992Q30977943-E2D7D588-E493-494B-B478-1BC0C32B359EQ31045586-E948E656-7C09-4768-8371-3B896963C606Q31058551-F6D03072-F871-41C9-B097-647B2DD2B15BQ33496256-B5617383-1492-4439-AA81-441B8103D418Q33612147-CBF2BE7A-A81E-46B1-A16E-B8B58D66BE6FQ33685944-43DD6C13-2673-495B-A4EF-953CA221D2FFQ33799937-8EA98B16-ABED-4FAA-81FD-D527284A5DA7Q33848621-FD02965E-B813-4F15-8E8B-4C6C5B438A49Q33912991-E095D7EC-9C8C-43EC-902E-73ED35545667Q34020532-0101F2CC-2CF1-4AC2-B235-F5F273BB6D8DQ34061851-1E927DCC-146D-4562-A790-1C1FD78882E6Q34260323-FD92A5DB-FBC2-4BE6-B46E-C827BE0C51EEQ34325302-68F8A7FD-8490-42DA-B9EB-C69A8220A44FQ34327769-B9242D5D-3506-457C-9F1E-D37280AD91BCQ34447720-39823FBC-1BF1-41F2-B40A-E1243B16CCDCQ34512441-9F418888-D160-458F-9D15-7D6AEF563E1AQ34513939-F452CC81-4C28-484B-B77B-E196A2FF9817Q34521956-FE7C1EC9-4181-4AD9-957E-F095B8152434Q34546584-4952A605-CC34-464C-8CA8-5C0148C9C289Q34552778-567A36B8-03C8-44BB-AA0C-7DD2D6E83B70Q34634984-1026C831-A682-4E43-A253-C4D00CBFC3B7Q34988437-AE76692D-3A73-4BF1-B213-D18FB4A9A983Q35041190-7F1686AB-4F5D-40B6-BC46-0C2B92ADB795Q35043600-1E3BDC87-ED20-405E-8B92-C0C13A46C3CC
P2860
The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The cholinergic hypothesis of ...... ns for novel drug development.
@ast
The cholinergic hypothesis of ...... ns for novel drug development.
@en
type
label
The cholinergic hypothesis of ...... ns for novel drug development.
@ast
The cholinergic hypothesis of ...... ns for novel drug development.
@en
prefLabel
The cholinergic hypothesis of ...... ns for novel drug development.
@ast
The cholinergic hypothesis of ...... ns for novel drug development.
@en
P356
P1476
The cholinergic hypothesis of ...... ns for novel drug development.
@en
P2093
Buccafusco JJ
Terry AV Jr
P304
P356
10.1124/JPET.102.041616
P407
P577
2003-06-12T00:00:00Z